Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Amortizatization of Intangibles (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Amortizatization of Intangibles rose 232.51% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 272.5% year-over-year, with the annual reading at $5.0 million for FY2025, 272.5% up from the prior year.
  • Amortizatization of Intangibles hit $2.0 million in Q4 2025 for Ligand Pharmaceuticals, up from $1.3 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $2.0 million in Q4 2025 to a low of -$150000.0 in Q1 2021.
  • Historically, Amortizatization of Intangibles has averaged $374000.0 across 5 years, with a median of $218000.0 in 2023.
  • Biggest five-year swings in Amortizatization of Intangibles: plummeted 82.93% in 2022 and later surged 5285.71% in 2023.
  • Year by year, Amortizatization of Intangibles stood at $34000.0 in 2021, then soared by 73.53% to $59000.0 in 2022, then skyrocketed by 544.07% to $380000.0 in 2023, then skyrocketed by 59.47% to $606000.0 in 2024, then soared by 232.51% to $2.0 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for LGNDZ at $2.0 million in Q4 2025, $1.3 million in Q3 2025, and $766000.0 in Q2 2025.